• Revenue up 83% to $10.5 million, driven by strong demand for Advanced Therapies
• Loss before tax narrowed by 19.5% to $3.3 million
• Secured $20 million asset-based loan facility to support growth and expansion

IDT Australia Limited has reported a strong performance in the first half of the 2025 financial year, with revenue surging 83% to $10.5 million compared to the prior corresponding period. The company's loss before tax narrowed by 19.5% to $3.3 million, reflecting the success of its strategic transformation over the past two years. The growth was primarily driven by the Advanced Therapies vertical, which recorded revenue of $3.9 million, up from $323,000 in the prior corresponding period. This reflects the company's strategy to shift its sales mix towards the higher-margin Advanced Therapies business, which is leveraged to the growing global demand for Antibody Drug Conjugates (ADC) and messenger RNA (mRNA) technologies. The performance of the API Manufacturing and Specialty Orals verticals was more mixed, with API Manufacturing revenue declining 63.6% to $1 million due to timing of orders, while Specialty Orals revenue fell 7.1% to $2 million as the company deliberately shifted focus to the Advanced Therapies business. However, the company expects the API and Specialty Orals verticals to improve significantly in the coming periods, with a recent $4 million in new contract wins. To support its growth and expansion plans, IDT Australia has secured a $20 million asset-based loan facility from Scottish Pacific Business Finance Pty Ltd, with a minimum drawdown of $10 million. This facility, along with the company's cash reserves of $1.1 million, will provide the necessary funding to execute its strategies and projects, as well as extend its production and manufacturing capabilities.

IDT Australia expects a significant improvement in the performance of its API Manufacturing and Specialty Orals verticals over the coming periods, driven by recent contract wins totaling close to $4 million in the December 2024 quarter.

IDT Australia is well-positioned to capitalize on the growing global demand for Advanced Therapies, such as Antibody Drug Conjugates (ADC) and messenger RNA (mRNA) technologies, as it continues to execute its strategic transformation and expand its production and manufacturing capabilities with the support of its new $20 million asset-based loan facility.